Гиполипидемическая эффективность ципрофибрата у больных ишемической болезнью сердца с дислипидемией в долгосрочном проспективном наблюдении

To investigate the influence of ciprafibrate on lipid metabolism in patients with ischemic heart disease (IHD) and mixed hyperlipidemia (HLD), the monitoring of plasma lipids and high density lipoproteins (IDL) was performed Result, obtained after 21 days, 3, 6 and 12 months of treatment, were compared with those obtained in healthy subjects. Baseline lipid status in parients with IHD characterized by HLE, HTE, HCE, high lipogenesis activity, reduced cholesterol esterification processes in plasma decreased oxidizing ability of lipids, destabilization of lipid structure of nucleus and superficial layer of HDL. After 21 day of treatment the autoregulatory level of lipids became similar to that of the healthy subjects and remains stable, when measured at 3., 6 and 12 months. The investigation of lipid metabolism, performed on molecular level, in patients with IHD, treated with ciprafibrate, reveals the normalization of metabolic process in all stages. The optimization of lipid structure results in activation of cholesterol transport to lever. Clinical examination confirms benefits of ciprafibrate treatment in patients with IHD and HLD. It expressed in improvement of life quality and significant increasing of exercise tolerance